Total Payments
$7,026
2024 Payments
$35.97
Companies
8
Transactions
17
Medicare Patients
1,593
Medicare Billing
$262,882
Payment Breakdown by Category
Consulting$5,550 (79.0%)
Travel$986.25 (14.0%)
Food & Beverage$412.41 (5.9%)
Education$76.95 (1.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $5,550 | 2 | 79.0% |
| Travel and Lodging | $986.25 | 4 | 14.0% |
| Food and Beverage | $412.41 | 10 | 5.9% |
| Education | $76.95 | 1 | 1.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $5,679 | 9 | $0 (2019) |
| Adaptive Biotechnologies Corporation | $1,057 | 2 | $0 (2021) |
| BeiGene USA, Inc. | $111.91 | 1 | $0 (2022) |
| Takeda Pharmaceuticals U.S.A., Inc. | $76.95 | 1 | $0 (2021) |
| Hologic Sales and Service, LLC | $35.97 | 1 | $0 (2024) |
| Hologic, LLC | $31.75 | 1 | $0 (2022) |
| Seagen Inc. | $18.71 | 1 | $0 (2021) |
| Novartis Pharmaceuticals Corporation | $14.23 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $35.97 | 1 | Hologic Sales and Service, LLC ($35.97) |
| 2022 | $143.66 | 2 | BeiGene USA, Inc. ($111.91) |
| 2021 | $153.12 | 3 | Takeda Pharmaceuticals U.S.A., Inc. ($76.95) |
| 2020 | $1,000 | 1 | Adaptive Biotechnologies Corporation ($1,000) |
| 2019 | $5,679 | 9 | AstraZeneca Pharmaceuticals LP ($5,679) |
| 2018 | $14.23 | 1 | Novartis Pharmaceuticals Corporation ($14.23) |
All Payment Transactions
17 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 04/17/2024 | Hologic Sales and Service, LLC | 3DQUORUM (Device) | Food and Beverage | In-kind items and services | $35.97 | General |
| Category: Breast and Skeletal Health | ||||||
| 11/02/2022 | Hologic, LLC | 3DQUORUM (Device) | Food and Beverage | In-kind items and services | $31.75 | General |
| Category: Breast and Skeletal Health | ||||||
| 06/28/2022 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $111.91 | General |
| Category: Oncology | ||||||
| 09/30/2021 | Seagen Inc. | ADCETRIS (Biological) | Food and Beverage | In-kind items and services | $18.71 | General |
| Category: Oncology | ||||||
| 08/18/2021 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Food and Beverage | In-kind items and services | $57.46 | General |
| Category: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | ||||||
| 04/21/2021 | Takeda Pharmaceuticals U.S.A., Inc. | — | Education | In-kind items and services | $76.95 | General |
| 12/29/2020 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| Category: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | ||||||
| 04/17/2019 | AstraZeneca Pharmaceuticals LP | IMFINZI (Drug) | Consulting Fee | Cash or cash equivalent | $4,550.00 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 04/13/2019 | AstraZeneca Pharmaceuticals LP | IMFINZI (Drug) | Travel and Lodging | In-kind items and services | $508.86 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 04/13/2019 | AstraZeneca Pharmaceuticals LP | IMFINZI (Drug) | Travel and Lodging | In-kind items and services | $289.75 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 04/13/2019 | AstraZeneca Pharmaceuticals LP | IMFINZI (Drug) | Travel and Lodging | In-kind items and services | $137.50 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 04/13/2019 | AstraZeneca Pharmaceuticals LP | IMFINZI (Drug) | Travel and Lodging | In-kind items and services | $50.14 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 04/13/2019 | AstraZeneca Pharmaceuticals LP | IMFINZI (Drug) | Food and Beverage | In-kind items and services | $43.20 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 04/13/2019 | AstraZeneca Pharmaceuticals LP | IMFINZI (Drug) | Food and Beverage | In-kind items and services | $40.00 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 04/13/2019 | AstraZeneca Pharmaceuticals LP | IMFINZI (Drug) | Food and Beverage | In-kind items and services | $35.18 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 04/13/2019 | AstraZeneca Pharmaceuticals LP | IMFINZI (Drug) | Food and Beverage | In-kind items and services | $24.00 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 04/19/2018 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $14.23 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2022 | 11 | 322 | 1,210 | $219,450 | $56,982 |
| 2021 | 18 | 586 | 18,850 | $343,179 | $103,850 |
| 2020 | 24 | 685 | 17,008 | $420,563 | $102,050 |
Total Patients
1,593
Total Services
37,068
Medicare Billing
$262,882
Procedure Codes
53
All Medicare Procedures & Services
53 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 45 | 157 | $63,297 | $22,759 | 36.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 93 | 132 | $39,870 | $11,894 | 29.8% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 20 | 81 | $57,660 | $9,311 | 16.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 62 | 76 | $16,097 | $4,926 | 30.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 16 | 16 | $8,250 | $2,894 | 35.1% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2022 | 19 | 40 | $13,278 | $2,265 | 17.1% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2022 | 12 | 96 | $9,819 | $1,275 | 13.0% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2022 | 11 | 23 | $2,530 | $612.62 | 24.2% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 19 | 50 | $5,866 | $588.08 | 10.0% |
| 96361 | Infusion into a vein for hydration, each additional hour | Office | 2022 | 13 | 39 | $2,733 | $417.63 | 15.3% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2022 | 12 | 500 | $50.00 | $38.86 | 77.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 144 | 313 | $82,735 | $31,414 | 38.0% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 52 | 121 | $43,893 | $17,819 | 40.6% |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 2021 | 19 | 16,320 | $28,415 | $12,583 | 44.3% |
| 96413 | Infusion of chemotherapy into a vein up to 1 hour | Office | 2021 | 26 | 102 | $72,420 | $12,475 | 17.2% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 88 | 125 | $22,450 | $8,349 | 37.2% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 39 | 39 | $18,915 | $7,142 | 37.8% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis up to 1 hour | Office | 2021 | 24 | 39 | $12,324 | $2,399 | 19.5% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 17 | 17 | $6,562 | $2,310 | 35.2% |
| 96375 | Injection of different drug or substance into a vein for therapy, diagnosis, or prevention | Office | 2021 | 20 | 138 | $14,076 | $1,963 | 13.9% |
| 96367 | Infusion into a vein for therapy prevention or diagnosis additional sequential infusion up to 1 hour | Office | 2021 | 11 | 55 | $7,755 | $1,469 | 18.9% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2021 | 25 | 49 | $1,911 | $1,339 | 70.1% |
| 96360 | Hydration infusion into a vein 31 minutes to 1 hour | Office | 2021 | 13 | 43 | $11,352 | $1,301 | 11.5% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2021 | 33 | 96 | $11,232 | $1,133 | 10.1% |
| 96361 | Hydration infusion into a vein | Office | 2021 | 18 | 94 | $6,580 | $1,091 | 16.6% |
About Dr. Nancy Chun, MD
Dr. Nancy Chun, MD is a Hematology & Oncology healthcare provider based in Nashua, New Hampshire. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/31/2006. The National Provider Identifier (NPI) number assigned to this provider is 1356302822.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Nancy Chun, MD has received a total of $7,026 in payments from pharmaceutical and medical device companies, with $35.97 received in 2024. These payments were reported across 17 transactions from 8 companies. The most common payment nature is "Consulting Fee" ($5,550).
As a Medicare-enrolled provider, Chun has provided services to 1,593 Medicare beneficiaries, totaling 37,068 services with total Medicare billing of $262,882. Data is available for 3 years (2020–2022), covering 53 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Nashua, NH
- Active Since 03/31/2006
- Last Updated 02/20/2019
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1356302822
Products in Payments
- IMFINZI (Drug) $5,679
- clonoSEQ (Device) $1,057
- BRUKINSA (Drug) $111.91
- 3DQUORUM (Device) $67.72
- ADCETRIS (Biological) $18.71
- KISQALI (Drug) $14.23
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Nashua
Yugandhara Kate, Md, MD
Hematology & Oncology — Payments: $573.74
Hematology & Oncology $573.74
Dr. Gautami Rao, M.d.,, M.D.,
Hematology & Oncology — Payments: $329.98
Hematology & Oncology $329.98
Can Wang
Hematology & Oncology — Payments: $107.82
Hematology & Oncology $107.82
Dr. Mary Voltz, M.d, M.D
Hematology & Oncology — Payments: $102.76
Hematology & Oncology $102.76